Australian clinical-stage drug development company Noxopharm (ASX: NOX) announced the filing of an international patent application aimed at protecting the use of Veyonda (Idronoxil) to block the development of infection-related septic shock.
Veyonda is being developed as a cancer drug with the potential to improve the effectiveness of existing cancer treatments.
“One of his anti-cancer measures is to block a signaling pathway called STING, which triggers an immune response and helps repair damaged tissue. In some people, the STING response is inappropriately high, causing the person to go into septic shock, ”the company said.
“Veyonda appears to be the first drug to block STING in the clinic,” it said.
Septic shock occurs in response to viral and bacterial infections by viruses and a variety of bacterial infections and parasites when an inappropriate, dramatic, and self-destructive inflammatory response occurs. A large number of inflammatory chemicals known as cytokines are released into the blood, leading to a number of problems such as clotting, which leads to damage to multiple organs and death. The chemical reaction is known as cytokine release syndrome (CRS), and the whole process is known as septic shock.
The company said septic shock will account for an estimated ten million deaths worldwide each year, with an estimated additional three million additional deaths due to the current pandemic to add to that number.
“Veyonda’s goal is to block the cytokine cascade that results from an inappropriately high STING response. The aim is to use Veyonda in patients with poor lung function and prevent them from falling over into CRS, thereby reducing the incidence of long-term disabilities and deaths and reducing the burden on medical care, “the company added.
/ Public release. This material is from the original organization and may be of a temporal nature and may be edited for clarity, style and length. Full view here.
Comments are closed.